(Q46110053)

19 December 2017

title

Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma (English)

1 reference

19 December 2017

main subject

phase II clinical trial

0 references

1 reference

1 reference

Edward Neely Atkinson

4

object named as

Neely Atkinson

1 reference

19 December 2017

author name string

Lois M Ramondetta

1

1 reference

19 December 2017

Alaina J Johnson

2

1 reference

19 December 2017

Charlotte C Sun

3

1 reference

19 December 2017

Judith A Smith

5

1 reference

19 December 2017

Maria S Jung

6

1 reference

19 December 2017

Russel Broaddus

7

1 reference

19 December 2017

Revathy B Iyer

8

1 reference

19 December 2017

Thomas Burke

9

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

19 December 2017

published in

Cancer

1 reference

19 December 2017

volume

115

1 reference

19 December 2017

issue

9

1 reference

19 December 2017

page(s)

1867-1874

1 reference

19 December 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Endometrial Stromal Sarcoma: Analysis of Treatment Failures and Survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Low-grade endometrial stromal sarcoma: hormonal aspects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Adjuvant chemotherapy for high-risk endometrial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Hormone therapy in advanced and recurrent endometrial cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Low-grade stromal sarcoma: a benign appearing malignant uterine tumour; a review of current literature. Differential diagnostic problems illustrated by four cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Pharmacological properties of mifepristone: toxicology and safety in animal and human studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Mechanism of action of progesterone antagonists

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Effects of luteal phase administration of mifepristone (RU486) and prostaglandin analogue or inhibitor on endometrium in the rhesus monkey

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Contraceptive use of antiprogestin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Phase II study of mifepristone (RU486) in refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24197

7 January 2021

Identifiers

DOI

10.1002/CNCR.24197

1 reference

19 December 2017

release_ovnxhojp7babzjsr46xnmdugd4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ovnxhojp7babzjsr46xnmdugd4

24 November 2022

mapped directly with Wikidata item

1 reference

19 December 2017